{"id":"talazoparib-avelumab","safety":{"commonSideEffects":[{"effect":"Fatigue","drugRate":"55.8%","placeboRate":"","totalAtRisk":52,"totalAffected":29,"trialsReporting":2},{"effect":"Anemia","drugRate":"53.8%","placeboRate":"","totalAtRisk":52,"totalAffected":28,"trialsReporting":2},{"effect":"Nausea","drugRate":"34.6%","placeboRate":"","totalAtRisk":52,"totalAffected":18,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"40.5%","placeboRate":"","totalAtRisk":42,"totalAffected":17,"trialsReporting":1},{"effect":"Diarrhea","drugRate":"28.8%","placeboRate":"","totalAtRisk":52,"totalAffected":15,"trialsReporting":2},{"effect":"Weight loss","drugRate":"31.0%","placeboRate":"","totalAtRisk":42,"totalAffected":13,"trialsReporting":1},{"effect":"White blood cell decreased","drugRate":"31.0%","placeboRate":"","totalAtRisk":42,"totalAffected":13,"trialsReporting":1},{"effect":"Lymphocyte count decreased","drugRate":"28.6%","placeboRate":"","totalAtRisk":42,"totalAffected":12,"trialsReporting":1},{"effect":"Anorexia","drugRate":"28.6%","placeboRate":"","totalAtRisk":42,"totalAffected":12,"trialsReporting":1},{"effect":"Cough","drugRate":"23.1%","placeboRate":"","totalAtRisk":52,"totalAffected":12,"trialsReporting":2},{"effect":"Dyspnea","drugRate":"23.1%","placeboRate":"","totalAtRisk":52,"totalAffected":12,"trialsReporting":2},{"effect":"Neutrophil count decreased","drugRate":"21.2%","placeboRate":"","totalAtRisk":52,"totalAffected":11,"trialsReporting":2},{"effect":"Vomiting","drugRate":"17.3%","placeboRate":"","totalAtRisk":52,"totalAffected":9,"trialsReporting":2},{"effect":"Pain","drugRate":"21.4%","placeboRate":"","totalAtRisk":42,"totalAffected":9,"trialsReporting":1},{"effect":"Alkaline phosphatase increased","drugRate":"21.4%","placeboRate":"","totalAtRisk":42,"totalAffected":9,"trialsReporting":1},{"effect":"Constipation","drugRate":"15.4%","placeboRate":"","totalAtRisk":52,"totalAffected":8,"trialsReporting":2},{"effect":"Hypoalbuminemia","drugRate":"19.0%","placeboRate":"","totalAtRisk":42,"totalAffected":8,"trialsReporting":1},{"effect":"Headache","drugRate":"15.4%","placeboRate":"","totalAtRisk":52,"totalAffected":8,"trialsReporting":2},{"effect":"Hypokalemia","drugRate":"16.7%","placeboRate":"","totalAtRisk":42,"totalAffected":7,"trialsReporting":1},{"effect":"Hyponatremia","drugRate":"16.7%","placeboRate":"","totalAtRisk":42,"totalAffected":7,"trialsReporting":1},{"effect":"Creatinine increased","drugRate":"11.5%","placeboRate":"","totalAtRisk":52,"totalAffected":6,"trialsReporting":2},{"effect":"Dizziness","drugRate":"14.3%","placeboRate":"","totalAtRisk":42,"totalAffected":6,"trialsReporting":1},{"effect":"Peripheral sensory neuropathy","drugRate":"14.3%","placeboRate":"","totalAtRisk":42,"totalAffected":6,"trialsReporting":1},{"effect":"Insomnia","drugRate":"11.5%","placeboRate":"","totalAtRisk":52,"totalAffected":6,"trialsReporting":2},{"effect":"Pruritus","drugRate":"14.3%","placeboRate":"","totalAtRisk":42,"totalAffected":6,"trialsReporting":1},{"effect":"Hypotension","drugRate":"14.3%","placeboRate":"","totalAtRisk":42,"totalAffected":6,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"9.6%","placeboRate":"","totalAtRisk":52,"totalAffected":5,"trialsReporting":2},{"effect":"Infusion related reaction","drugRate":"11.9%","placeboRate":"","totalAtRisk":42,"totalAffected":5,"trialsReporting":1},{"effect":"Dehydration","drugRate":"11.9%","placeboRate":"","totalAtRisk":42,"totalAffected":5,"trialsReporting":1},{"effect":"Hyperglycemia","drugRate":"11.9%","placeboRate":"","totalAtRisk":42,"totalAffected":5,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"11.9%","placeboRate":"","totalAtRisk":42,"totalAffected":5,"trialsReporting":1},{"effect":"Hypertension","drugRate":"11.9%","placeboRate":"","totalAtRisk":42,"totalAffected":5,"trialsReporting":1},{"effect":"Dry mouth","drugRate":"9.5%","placeboRate":"","totalAtRisk":42,"totalAffected":4,"trialsReporting":1},{"effect":"Chills","drugRate":"9.5%","placeboRate":"","totalAtRisk":42,"totalAffected":4,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"9.5%","placeboRate":"","totalAtRisk":42,"totalAffected":4,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"9.5%","placeboRate":"","totalAtRisk":42,"totalAffected":4,"trialsReporting":1},{"effect":"Rash maculo-papular","drugRate":"9.5%","placeboRate":"","totalAtRisk":42,"totalAffected":4,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Dysphagia","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Toothache","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Fever","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Non-cardiac chest pain","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Generalized muscle weakness","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Myalgia","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Paresthesia","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Pneumonitis","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Alopecia","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1},{"effect":"Dry skin","drugRate":"7.1%","placeboRate":"","totalAtRisk":42,"totalAffected":3,"trialsReporting":1}]},"_chembl":{"chemblId":"CHEMBL3833373","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T11:34:08.919813","allNames":"talazoparib + avelumab","_dailymed":null,"mechanism":{"target":"PARP, PD-L1","drugClass":"PARP inhibitor, PD-L1 inhibitor","explanation":"Talazoparib prevents DNA repair in cancer cells by inhibiting PARP enzymes, leading to cell death. Avelumab binds to PD-L1, blocking its interaction with PD-1 and stimulating the immune system to attack cancer cells.","oneSentence":"Talazoparib inhibits PARP enzymes, while avelumab blocks PD-L1, enhancing immune response against cancer cells."},"_scrapedAt":"2026-03-28T01:47:52.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:46:46.824813+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT04678362","phase":"PHASE2","title":"TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma","status":"RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2021-06-01","conditions":"Urothelial Carcinoma","enrollment":50},{"nctId":"NCT02912572","phase":"PHASE2","title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-14","conditions":"Metastatic Endometrial Cancer","enrollment":106},{"nctId":"NCT05059522","phase":"PHASE3","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-09-29","conditions":"Advanced Malignancies, NSCLC, Ovarian Cancer","enrollment":68},{"nctId":"NCT03964532","phase":"PHASE1, PHASE2","title":"TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2019-04-17","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT04068831","phase":"PHASE2","title":"Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-08-22","conditions":"Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT04173507","phase":"PHASE2","title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2020-02-14","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT03330405","phase":"PHASE1, PHASE2","title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-10-19","conditions":"Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors","enrollment":223},{"nctId":"NCT03565991","phase":"PHASE2","title":"Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-06-18","conditions":"Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1","enrollment":202},{"nctId":"NCT03642132","phase":"PHASE3","title":"Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-07-19","conditions":"Ovarian Cancer","enrollment":79},{"nctId":"NCT03637491","phase":"PHASE1, PHASE2","title":"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-08-15","conditions":"Pancreatic Cancer","enrollment":36},{"nctId":"NCT04052204","phase":"PHASE1, PHASE2","title":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Talazoparib + Avelumab","genericName":"talazoparib-avelumab","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"Talazoparib and Avelumab are being studied in a clinical trial for metastatic renal cell carcinoma, among other conditions. Avelumab is an antibody that targets the programmed cell death 1 ligand 1 (PD-L1) molecular target.","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:46:46.824813+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}